Three new board members for Bacterin
This article was originally published in Clinica
Bioactive coating specialist Bacterin International has appointed three "seasoned financial experts" to its board of directors: Daniel Frank, Gary Simon and Ken Calligar. Mr Frank has 31 years of asset management experience with a focus on the healthcare industry. He has served on several company boards including stent developer Reva Medical and point-of-care testing firm i-STAT. Mr Simon is currently a manager of UVE Partners, an investment fund that he co-founded. Before this, he was senior vice-president of investment banking firm Barington Capital Group. Mr Calligar is the founder and managing partner of investment banking firm Convertible Capital, and was previously a managing director of Jefferies & Co. He has over 25 years' experience in the financial industry. Belgrade, Montana-based Bacterin develops coatings for medical devices, transplants and tissue products.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.